Lupin is expected to report continued weakness in its US business due to higher competition in its large generic products. We expect 5% yoy growth in revenue while EBITDA and PAT are expected to decline 29% and 37% yoy, respectively.
To Get Free Trial
Missed call @ 9582541010
Call Us @ 8822117117
Mail Us = starindiamarket@gmail.com
Visit = http://www.starindiaresearch.com/freetrail.php
To Get Free Trial
Missed call @ 9582541010
Call Us @ 8822117117
Mail Us = starindiamarket@gmail.com
Visit = http://www.starindiaresearch.com/freetrail.php
No comments:
Post a Comment